ID Board Review/Antimicrobial Therapy/Antibacterials/Antipseudomonal
Appearance
β-Lactams with β-Lactamase inhibitors
[edit | edit source]- Piperacillin/Tazobactam
- Ticarcillin/Clavulanate
Carbapenems
[edit | edit source]- Meropenem
- Imipenem
- Doripenem
Fourth Generation Cephalosporins
[edit | edit source]- Ceftazidime
- Cefepime
Notes
[edit | edit source]Double Coverage
[edit | edit source]- Recommended by some experts under certain circumstances[1]
- Pts at risk for antimicrobial resistance:
- IV Abx w/n 90 days
- VAP with septic shock
- ARDS preceding VAP
- ≥5 days hospitalization prior to occurrence of VAP
- Acute renal replacement therapy prior to VAP
- Pts with structural lung disease (ie bronchiectasis or cystic fibrosis)
- If >10% gram-negative isolates are resistant to an agent being considered for monotherapy
- If local antimicrobial susceptibility is unknown
- Pts at risk for antimicrobial resistance:
- Double antipseudomonal coverage should have 2 different classes;
- A β-lactam + ...
- A Fluoroquinolone, OR
- An Aminoglycoside
- Aminoglycosides and Fluoroquinolones are not used as monotherapy
- A β-lactam + ...
- Abx should be narrowed to one, based on sensitivities
Preferred Antipseudomonal Coverage for CNS Infections
[edit | edit source]- Cefepime,
- Ceftazidime, OR
- Meropenem
Resistances
[edit | edit source]- Monobactams e.g. Aztreonam have a high resistance rate, but may be used in Pts with penicillin allergies.